The influence of the blood handling process on the measurement of circulating TGF-β1

European Cytokine Network

Volumn 23, Issue 1, 2012, Pages 1-6

  Zhao, Lujun ^a,b   Wang, Luhua ^a   Ji, Wei ^a   Lei, Mingfang ^a   Yang, Weizhi ^a   Kong, Feng Ming ^c,d  

^a CANCER HOSPITAL   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d Ann Arbor Veteran Administration Health Center   (United States)

Author keywords

Plasma; Platelet; Serum; Transforming growth factor

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; BLOOD SAMPLING; CENTRIFUGATION; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; STUDENT T TEST;

ADULT; BLOOD PRESERVATION; CENTRIFUGATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PLASMA; REPRODUCIBILITY OF RESULTS; SERUM; SPECIMEN HANDLING; TEMPERATURE; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84859307803     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2012.0298     Document Type: Article

References (41)

1. Zhao L, Ji W, Zhang L, et al. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer. J Thorac Oncol 2010; 5: 521.
2. Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer 1996; 16: 47.
3. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995; 222: 155.
4. Kong FM, Anscher MS, Jirtle RL. Transforming Growth Factor Beta: A Plasma Tumor Marker In: Hanausek M,Walaszek Z, eds. Methods in Molecular Biology: Tumor Marker Protocols. NewJersey: Human Press Inc., 1997; 417.
5. Grainger DJ, Mosedale DE, Metcalfe JC. TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev 2000; 11: 133.
6. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 1983; 258: 7155.
7. Jeon JH, Kim YS, Choi EJ, et al. Implication of co-measured platelet factor 4 in the reliability of the results of the plasma transforming growth factor-beta 1 measurement. Cytokine 2001; 16: 102.
8. Zhao L, Wang L, Ji W, et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan. Int J Radiat Oncol Biol Phys 2009; 74: 1385.
9. Anscher MS, Kong FM, Andrews K, et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998; 41: 1029.
10. Evans ES, Kocak Z, Zhou SM, et al. Does transforming growth factor-beta1 predict for radiation-induced pneumonitis in patients treated for lung cancer?. Cytokine 2006; 35: 186.
11. Rabbani ZN, Anscher MS, Zhang X, et al. Soluble TGFbeta type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Int J Radiat Oncol Biol Phys 2003; 57: 563.
12. Kong FM, Anscher MS, Sporn TA, et al. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2001; 49: 35.
13. Novakova-Jiresova A, Van Gameren MM, Coppes RP, Kampinga HH, Groen HJ. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 2004; 71: 183.
14. De Jaeger K, Seppenwoolde Y, Kampinga HH, Boersma LJ, Belderbos JS, Lebesque JV. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58: 1378.
15. Anscher MS, Kong FM. In regard to De Jaeger et al.: significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer (Int J Radiat Oncol Biol Phys 2004; 58:1378-1387). Int J Radiat Oncol Biol Phys 2005; 61:1276.
16. Barthelemy-Brichant N. Determination of TGF-beta1 plasma levels: In regard to Anscher et al. (Int J Radiat Oncol Biol Phys 2003; 56: 988-995) and de Jaeger et al (Int J Radiat Oncol Biol Phys 2004; 58: 1378-1387). Int J Radiat Oncol Biol Phys 2004; 60:1339; author reply 1339.
17. De Jaeger K, Seppenwoolde Y, Lebesque JV, Kampinga HH. In response to Drs. Anscher and Kong. Int J Radiat Oncol Biol Phys 2005; 63: 308.
18. Anscher MS, Kong FM, Marks LB, Bentel GC, Jirtle RL. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 1997; 37: 253.
19. Anscher MS. Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy. Oncologist 2010; 15: 350.
20. Gomes FC, Sousa Vde O, Romao L. Emerging roles for TGFbeta1 in nervous system development. Int J Dev Neurosci 2005; 23: 413.
21. Ghosh J, Murphy MO, Turner N, et al. The role of transforming growth factor beta1 in the vascular system. Cardiovasc Pathol 2005; 14: 28.
22. Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest 2004; 125: 754.
23. Peterson MC. Circulating transforming growth factor beta-1: a partial molecular explanation for associations between hypertension, diabetes, obesity, smoking and human disease involving fibrosis. Med Sci Monit 2005; 11: RA229.
24. Glick AB. TGFbeta1, back to the future: revisiting its role as a transforming growth factor. Cancer Biol Ther 2004; 3: 276.
25. Mohammad KS, Javelaud D, Fournier PG, et al. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 2011; 71: 175.
26. Junker U, Knoefel B, Nuske K, et al. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine 1996; 8: 794.
27. Pfeiffer A, Middelberg-Bisping K, Drewes C, Schatz H. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care 1996; 19: 1113.
28. Harrison P, Cramer EM. Platelet alpha-granules. Blood Rev 1993; 7: 52.
29. von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 2007; 97: 704.
30. van Waarde MA, van Assen AJ, Kampinga HH, Konings AW, Vujaskovic Z. Quantification of transforming growth factor-beta in biological material using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1997; 247: 45.
31. Grainger DJ, Mosedale DE, Metcalfe JC, Weissberg PL, Kemp PR. Active and acid-activatable TGF-beta in human sera, platelets and plasma. Clin Chim Acta 1995; 235: 11.
32. Coupes BM, Williams S, Roberts IS, Short CD, Brenchley PE. Plasma transforming growth factor beta(1) and platelet activation: implications for studies in transplant recipients. Nephrol Dial Transplant 2001; 16: 361.
33. Esmatjes E, Flores L, Inigo P, Lario S, Ruilope LM, Campistol JM. Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001; 16 Suppl 1: 90.
34. Wakefield LM, Letterio JJ, Chen T, et al. Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995; 1: 129.
35. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62: 343.
36. Wynendaele W, Derua R, Hoylaerts MF, et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?. Ann Oncol 1999; 10: 965.
37. Dittadi R, Meo S, Fabris F, et al. Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers 2001; 16: 87.
38. Byrne GJ, McDowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ. Serum vascular endothelial growth factor in breast cancer. Anticancer Res 2007; 27: 3481.
39. Hormbrey E, Gillespie P, Turner K, et al. A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful? Clin Exp Metastasis 2002; 19: 651.
40. Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol 2000; 17: 149.
41. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 2003; 10: 335.